Selexis SA, a Geneva, Switzerland-based provider of mammalian cell-line generation technology, has agreed to license its mammalian cell line-based protein expression platform (SUREtechnology) to Compugen, a Richmond Hill, Ontario, Canada-headquartered genomics-based drug and diagnostic discovery company.

Compugen plans to use Selexis’ SUREtechnology platform to develop antibody-based therapeutics targeting certain cancers, including to support further advancement of its lead immuno-oncology product candidate.

Compugen’s lead candidate is a humanized hybridoma antibody that binds to PVRIG, a B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with PVRL2. The candidate is currently in preclinical development with an investigational new drug application filing with the US Food and Drug Administration expected toward the end of the first quarter of 2018.

Source: Compugen